Nonacog alfa
BeneFIX (nonacog alfa) is a protein pharmaceutical. Nonacog alfa was first approved as Benefix on 1997-08-27. It is used to treat factor VII deficiency, hemophilia a, hemophilia b, and hypoprothrombinemias in the USA. It has been approved in Europe to treat hemophilia b.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| benefix | Biologic Licensing Application | 2010-12-16 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
163 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemophilia a | D006467 | EFO_0007267 | D66 | 32 | 25 | 45 | 14 | 47 | 146 |
| Hemophilia b | D002836 | — | D67 | 29 | 26 | 42 | 11 | 41 | 131 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | 1 | — | 3 | 2 | 1 | 7 |
| Hemostatic disorders | D020141 | — | — | 1 | — | 3 | 2 | 1 | 7 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 2 | 3 | — | 5 |
| Cardiac surgical procedures | D006348 | — | — | — | — | — | 2 | — | 2 |
| Joint diseases | D007592 | HP_0003040 | M12.9 | — | — | — | 1 | 1 | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | 1 | — | 1 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | 1 | — | 1 |
| Hemarthrosis | D006395 | EFO_1001344 | M25.0 | — | — | — | 1 | — | 1 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | — | 1 | — | — | 1 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | 1 | — | — | 1 |
| Hemorrhagic disorders | D006474 | — | D69.9 | — | — | 1 | — | — | 1 |
| Hemorrhagic shock | D012771 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombosis | D013927 | — | — | 1 | 1 | — | — | — | 2 |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | — | 1 | — | — | — | 1 |
| Embolism | D004617 | — | — | — | 1 | — | — | — | 1 |
| Thromboembolism | D013923 | HP_0001907 | — | — | 1 | — | — | — | 1 |
| Embolism and thrombosis | D016769 | — | — | — | 1 | — | — | — | 1 |
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | 1 | — | — | — | 1 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | 1 | — | — | — | 1 |
| Transsexualism | D014189 | — | F64.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | — | — | — | 2 | 2 |
| Mucopolysaccharidoses | D009083 | — | E76.3 | — | — | — | — | 1 | 1 |
| Mucopolysaccharidosis i | D008059 | — | E76.0 | — | — | — | — | 1 | 1 |
| Mucopolysaccharidosis ii | D016532 | — | E76.1 | — | — | — | — | 1 | 1 |
| Liver transplantation | D016031 | EFO_0010682 | — | — | — | — | — | 1 | 1 |
| Von willebrand diseases | D014842 | EFO_0003910 | D68.0 | — | — | — | — | 1 | 1 |
| Hemostasis | D006487 | — | — | — | — | — | — | 1 | 1 |
| Genetic therapy | D015316 | — | — | — | — | — | — | 1 | 1 |
| Osteoporosis | D010024 | HP_0000939 | M81.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nonacog alfa |
| INN | nonacog alfa |
| Description | BeneFIX (nonacog alfa) is a protein pharmaceutical. Nonacog alfa was first approved as Benefix on 1997-08-27. It is used to treat factor vii deficiency, hemophilia a, hemophilia b, and hypoprothrombinemias in the USA. It has been approved in Europe to treat hemophilia b. |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2109205 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 382L14738L (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Benefix – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 287 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,767 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use